Targeted HIF-1a to Treat Tumors: Mechanisms, Application and Future
DOI:
https://doi.org/10.61173/v8swtk03Keywords:
HIF-1a, tumor therapy, cancer, targeted drug therapyAbstract
Cancer has become one of the major health challenges in the world today. With the growth of population, the change of lifestyle and environmental pollution, the incidence of cancer is on the rise, which presents a major risk to the lives and health of people. At the same time, with the aging of the population and the change of lifestyle, the mortality rate of cancer continues to rise, which brings a heavy burden to society, families and individuals. At present, radiation therapy, chemotherapy, and surgical resection are the three primary cancer treatment methods.HIF-1a as a transcription factor is highly related to tumor proliferation, and related therapeutic strategies have great potential. This article provides an overview of the research on the relationship between HIF-1a and tumors, explains how HIF-1a can be used to stimulate tumor growth and stability, and lists some practical ways to use the HIF-1a transcription factor to treat tumors. It provides a new research direction reference and guidance for the frontier research of tumor therapy, and provides a new possible cure option for tumor patients.
References
[1] Hyuna S, Jacques F, L. R S, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] Karin E, Johanna A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023, 41(3): 374-403.
[3] Zamarud A, Shahnoor S, Maryyum A, et al. Therapeutic approaches for spinal synovial sarcoma: a comprehensive review of the literature. Journal of Neurosurgery, Spine, 2024: 1-8.
[4] Sharma P, Allison P J. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 2015, 161(2): 205-214.
[5] Choudhry H, Harris L A. Advances in Hypoxia-Inducible Factor Biology. Cell Metabolism, 2018, 27(2): 281-298.
[6] Zhang H, Gao P, Fukuda R, et al. HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL- Deficient Renal Cell Carcinoma by Repression of C-MYC Activity. Cancer Cell, 2007, 11(5): 407-420.
[7] Forsythe J A, Jiang B H, Iyer N V, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Molecular and Cellular Biology, 1996, 16(9): 4604-4613
[8] Brahimi-Horn M C, Bellot G, Pouysségur J. Hypoxia and energetic tumour metabolism. Current Opinion in Genetics & Development, 2011, 21(1): 67–72.
[9] Goda N, Dozier S J, Johnson R S. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxidants & Redox Signaling, 2003, 5(4): 467–473.
[10] Cui C P, Wong C C, et al. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut, 2017, 66(12): 2149–2159.
[11] Li Y, Zhang M Z, Zhang S J, et al. HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization. Biomedicine & Pharmacotherapy, 2023, 161: 114423.
[12] Zhu Y, Zang Y, Zhao F, et al. Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo. American Journal of Cancer Research, 2017, 7(5): 1198–1212.
[13] Tang X, Cui K, Lu X, et al. A Novel Hypoxia-inducible Factor 1α Inhibitor KC7F2 Attenuates Oxygen-induced Retinal Neovascularization. Investigative Ophthalmology & Visual Science, 2022, 63(6): 13.
[14] You P, Lin M, Li K, et al. Normobaric oxygen therapy inhibits HIF-1α and VEGF expression in perihematoma and reduces neurological function defects. Neuroreport, 2016, 27(5): 329–336.
[15] Zhu T, Cheng Z, Peng X, et al. HIF-1α RNAi Combined with Asparagus Polysaccharide Exerts an Antiangiogenesis Effect on Hepatocellular Carcinoma In Vitro and In Vivo. Evidence-based Complementary and Alternative Medicine: eCAM, 2021: 9987383.
[16] Zhao Z, Xia G, Li N. et al. Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells. Journal of Cancer, 2018, 9(18): 3407– 3416.
[17] Welsh S J, Williams R R, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics, 2003, 2(3): 235–243.
[18] Bailey C M, Liu Y, Peng G, et al. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29: 102278.
[19] Zhu Y, Zang Y, Zhao F, et al. Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo. American Journal of Cancer Research, 2017, 7(5): 1198–1212.
[20] Kang X, Chen K, Li Y, et al. Personalized targeted therapy for esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2015, 21(25): 7648–7658.
[21] Jin F, Ji H, Jia C, et al. Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116. PloS One, 2012, 10: e47161.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
